Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 90,841 |
|
|||||
| News | - | ||||||
| Day High | 1.61 | Low High |
|||||
| Day Low | 1.36 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Equillium Inc | EQ | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.08 | -5.30% | 1.43 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.51 | 1.36 | 1.61 | 1.43 | 1.51 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 480 | 90,841 | US$ 1.46 | US$ 133,079 | - | 0.45 - 3.25 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 18:30:09 | 1 | US$ 1.48 | USD |
Equillium Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 49.52M | 35.12M | - | 36.08M | -13.34M | -0.38 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Equillium News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EQ Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.56 | 1.66 | 1.36 | 1.54 | 46,708 | -0.13 | -8.33% |
| 1 Month | 1.79 | 1.89 | 1.32 | 1.60 | 91,337 | -0.36 | -20.11% |
| 3 Months | 2.50 | 2.985 | 1.32 | 2.19 | 163,247 | -1.07 | -42.80% |
| 6 Months | 0.50 | 3.25 | 0.478899 | 1.69 | 251,394 | 0.93 | 186.00% |
| 1 Year | 0.61 | 3.25 | 0.45 | 1.34 | 193,973 | 0.82 | 134.43% |
| 3 Years | 6.34 | 7.75 | 0.45 | 2.16 | 139,175 | -4.91 | -77.44% |
| 5 Years | 7.76 | 30.20 | 0.45 | 14.61 | 411,487 | -6.33 | -81.57% |
Equillium Description
| Equillium Inc is a biotechnology developing therapies to treat autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph 2 ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease. |
